scholarly journals Admission Glucose Level and In-hospital Outcomes in Diabetic and Non-diabetic Patients with ST-elevation Acute Myocardial Infarction

2011 ◽  
Vol 50 (21) ◽  
pp. 2471-2475 ◽  
Author(s):  
Li Dong-bao ◽  
Hua Qi ◽  
Guo Jincheng ◽  
Li Hong-wei ◽  
Chen Hui ◽  
...  
2010 ◽  
Vol 99 (11) ◽  
pp. 715-721 ◽  
Author(s):  
Artur Dziewierz ◽  
Dawid Giszterowicz ◽  
Zbigniew Siudak ◽  
Tomasz Rakowski ◽  
Jacek S. Dubiel ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Ozge Kurmus ◽  
Turgay Aslan ◽  
Berkay Ekici ◽  
Sezen Baglan Uzunget ◽  
Sukru Karaarslan ◽  
...  

In patients with acute myocardial infarction, glucose metabolism is altered and acute hyperglycemia on admission is common regardless of diabetes status. The development of coronary collateral is heterogeneous among individuals with coronary artery disease. In this study, we aimed to investigate whether glucose value on admission is associated with collateral flow in ST-elevation myocardial infarction (STEMI) patients. We retrospectively evaluated 190 consecutive patients with a diagnosis of first STEMI within 12 hours of onset of chest pain. Coronary collateral development was graded according to Rentrop classification. Rentrop 0-1 was graded as poor collateral development, and Rentrop 2-3 was graded as good collateral development. Admission glucose was measured and compared between two groups. Mean admission glucose level was 173.0 ± 80.1 mg/dl in study population. Forty-five (23.7%) patients had good collateral development, and 145 (76.3%) patients had poor collateral development. There were no statistically significant differences in demographic characteristics between two groups. Three-vessel disease was more common in patients with good collateral development (p=0.026). Mean admission glucose level was higher in patients with poor collateral than good collateral (180.6 ± 84.9 mg/dl versus 148.7 ± 56.6 mg/dl, resp., p=0.008). In univariate analysis, higher admission glucose was associated with poor collateral development, but multivariate logistic regression analysis revealed a borderline result (odds ratio 0.994, 95% CI 0.989–1.000, p=0.049). Our results suggest that elevated glucose on admission may have a role in the attenuation of coronary collateral blood flow in acute myocardial infarction. Further studies are needed to validate our results.


2010 ◽  
Vol 95 (11) ◽  
pp. 4993-5002 ◽  
Author(s):  
Marianne Zeller ◽  
Nicolas Danchin ◽  
Dominique Simon ◽  
Alec Vahanian ◽  
Luc Lorgis ◽  
...  

Background: The impact of antidiabetic medications on clinical outcomes in patients developing acute myocardial infarction (MI) is controversial. We sought to determine whether in-hospital outcomes in patients who were on sulfonylureas (SUs) when they developed their MIs differed from that of diabetic patients not receiving SUs and whether clinical outcomes were related to the pancreatic cells specificity of SUs. Methods and Results: We analyzed the outcomes of the 1310 diabetic patients included in the nationwide French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction in 2005. Medications used before the acute episode were recorded. In-hospital complications were analyzed according to prior antidiabetic treatment. Mortality was lower in patients previously treated with SUs (3.9%) vs. those on other oral medications (6.4%), insulin (9.4%), or no medication (8.4%) (P = 0.014). Among SU-treated patients, in-hospital mortality was lower in patients receiving pancreatic cells-specific SUs (gliclazide or glimepiride) (2.7%), compared with glibenclamide (7.5%) (P = 0.019). Arrhythmias and ischemic complications were also less frequent in patients receiving gliclazide/glimepiride. The lower risk in patients receiving gliclazide/glimepiride vs. glibenclamide persisted after multivariate adjustment (odds ratio 0.15; 95% confidence interval 0.04–0.56) and in propensity score-matched cohorts. Conclusion: In this nationwide registry of patients hospitalized for acute MI, no hazard was associated with the use of SUs before the acute episode. In addition, patients previously receiving gliclazide/glimepiride had improved in-hospital outcomes, compared with those on glibenclamide.


2010 ◽  
Vol 74 (8) ◽  
pp. 1651-1657 ◽  
Author(s):  
Tatsuya Maruhashi ◽  
Masaharu Ishihara ◽  
Ichirou Inoue ◽  
Takuji Kawagoe ◽  
Yuji Shimatani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document